research use only

Asiaticoside ROS inhibitor

Name: Asiaticoside
Brand: Selleck Chemicals
SKU: S3616
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S3616

Asiaticoside (Ba 2742, BRN0078195, CCRIS8995, NSC166062, Emdecassol,Madecassol), the major active principle of Centella asiatica, prevents ultraviolet A-dependent photoaging by suppressing ultraviolet A-induced reactive oxygen species production. It also decreases DNA binding by MITF.

Chemical Structure

Molecular Weight: 959.12

Jump to

Quality Control

Batch: Purity: 99.99%

99.99

Related Targets	PD-1/PD-L1 CXCR STING AhR Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX
Other ROS Products	MitoQ (Mitoquinone) Mesylate Piperlongumine H2DCFDA (DCFH-DA) Neohesperidin Carnosic acid Gallic acid (20R)Ginsenoside Rg3 Pyrogallol Idebenone Sarsasapogenin

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (104.26 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (5.21mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.830mg/ml (0.87mM)	Taking the 1 mL working solution as an example, add 50 μL of 16.6 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	959.12	Formula	C₄₈H₇₈O₁₉	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	16830-15-2	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Ba 2742, BRN0078195, CCRIS8995, NSC166062, Emdecassol,Madecassol			Smiles	CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CC(C(C5(C)CO)O)O)C)C)C2C1C)C)C(=O)OC6C(C(C(C(O6)COC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)C)O)O)O)O)O)O)O)O

Mechanism of Action

In vitro	In the central nervous system, Asiaticoside has been shown to attenuate in vitro neuronal damage caused by exposure to β-amyloid. In cultured mouse cortical neurons exposed to glutamate-induced excitotoxicity invoked by N-methyl-D-aspartate, pretreatment with this compound decreases neuronal cell loss in a concentration-dependent manner and restored changes in expression of apoptotic-related proteins Bcl-2 and Bax. This compound pretreatment also attenuates the upregulation of NR2B expression, a subunit of N-methyl-D-aspartate receptors, but does not affect expression of NR2A subunits. It also significantly inhibits Ca 2+ influx induced by N-methyl-D-aspartate. Presence of this chemical along with the DNA during irradiation prevents the relaxation of the supercoiled form to the open circular form.
In vivo	In vivo studies demonstrate that Asiaticoside could attenuate neurobehavioral, neurochemical and histological changes in transient focal middle cerebral artery occlusion animals. In addition, this compound shows anxiolytic effects in acute and chronic stress animals. It has been shown to have wound healing effects, anti-inflammatory effects, and promotes liver protective activity. Administration of this chemical prior to whole-body radiation exposure of the mice prevents this increase in radiation-induced increase in comet parameters, which could be the result of protection to DNA under in vivo conditions of radiation exposure.
References	[1] https://pubmed.ncbi.nlm.nih.gov/25221579/ [2] https://pubmed.ncbi.nlm.nih.gov/26756427/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03814850	Withdrawn	Unruptured Cerebral Aneurysm	Sebastian Koch\|University of Miami	December 1 2024	Not Applicable
NCT05287347	Not yet recruiting	Pancreatic Adenocarcinoma	Beth Israel Deaconess Medical Center\|National Institutes of Health (NIH)\|Dana-Farber Cancer Institute	October 2024	--
NCT06360094	Not yet recruiting	Idiopathic Pulmonary Fibrosis\|Progressive Pulmonary Fibrosis	Boehringer Ingelheim	July 27 2024	Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):